Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes
Abstract Patients with diabetes have a high risk of failure of H. pylori eradication therapy. The present study aims to evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for the treatment of H. pylori infection in patients with type-2 diabetes mellitus (T2DM), and determin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85628-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544744762605568 |
|---|---|
| author | Jie Zhang Xin Cao Kai Ma Yizhou Jiang Xiangrong Qin Xiaoyong Wang |
| author_facet | Jie Zhang Xin Cao Kai Ma Yizhou Jiang Xiangrong Qin Xiaoyong Wang |
| author_sort | Jie Zhang |
| collection | DOAJ |
| description | Abstract Patients with diabetes have a high risk of failure of H. pylori eradication therapy. The present study aims to evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for the treatment of H. pylori infection in patients with type-2 diabetes mellitus (T2DM), and determine the influence of H. pylori eradication on the glycated hemoglobin A1C (A1C) level. The present prospective, single-center, single-arm, clinical trial enrolled 75 T2DM patients diagnosed with H. pylori infection. The patients were treated with the VA dual therapy regimen, which comprised of vonoprazan (20 mg, twice daily) and amoxicillin (750 mg, thrice daily), for 14 days (14-day VA dual therapy). The eradication rate in the intention-to-treat analysis and per-protocol analysis was 84.00% (63/75) and 87.14% (61/70), respectively. The multivariate analysis revealed that the independent risk factors for H. pylori eradication failure were smoking (OR: 4.59, 95% CI: 1.20–17.58, p = 0.026) and elevated A1C level (OR: 1.65, 95% CI: 1.01–2.68, p = 0.044). Patients in the successful eradication group presented with a significant decrease in the A1C level at 3 months, post-treatment, when compared to the pre-eradication level (7.70 ± 1.05% vs. 7.23 ± 1.00%, p = 0.006). VA dual therapy is a safe and effective regimen for patients with T2DM. |
| format | Article |
| id | doaj-art-5ffd93d88b094b088d65bc7b7a1e69a8 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5ffd93d88b094b088d65bc7b7a1e69a82025-01-12T12:18:38ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-025-85628-5Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetesJie Zhang0Xin Cao1Kai Ma2Yizhou Jiang3Xiangrong Qin4Xiaoyong Wang5Department of Endocrinology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityDepartment of Gastroenterology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityDepartment of Gastroenterology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityDepartment of Gastroenterology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityDepartment of Gastroenterology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityDepartment of Gastroenterology, Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical UniversityAbstract Patients with diabetes have a high risk of failure of H. pylori eradication therapy. The present study aims to evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for the treatment of H. pylori infection in patients with type-2 diabetes mellitus (T2DM), and determine the influence of H. pylori eradication on the glycated hemoglobin A1C (A1C) level. The present prospective, single-center, single-arm, clinical trial enrolled 75 T2DM patients diagnosed with H. pylori infection. The patients were treated with the VA dual therapy regimen, which comprised of vonoprazan (20 mg, twice daily) and amoxicillin (750 mg, thrice daily), for 14 days (14-day VA dual therapy). The eradication rate in the intention-to-treat analysis and per-protocol analysis was 84.00% (63/75) and 87.14% (61/70), respectively. The multivariate analysis revealed that the independent risk factors for H. pylori eradication failure were smoking (OR: 4.59, 95% CI: 1.20–17.58, p = 0.026) and elevated A1C level (OR: 1.65, 95% CI: 1.01–2.68, p = 0.044). Patients in the successful eradication group presented with a significant decrease in the A1C level at 3 months, post-treatment, when compared to the pre-eradication level (7.70 ± 1.05% vs. 7.23 ± 1.00%, p = 0.006). VA dual therapy is a safe and effective regimen for patients with T2DM.https://doi.org/10.1038/s41598-025-85628-5Helicobacter pyloriType 2 diabetesDual therapyGlycemic control |
| spellingShingle | Jie Zhang Xin Cao Kai Ma Yizhou Jiang Xiangrong Qin Xiaoyong Wang Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes Scientific Reports Helicobacter pylori Type 2 diabetes Dual therapy Glycemic control |
| title | Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| title_full | Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| title_fullStr | Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| title_full_unstemmed | Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| title_short | Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| title_sort | safety and effectiveness of dual therapy for helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes |
| topic | Helicobacter pylori Type 2 diabetes Dual therapy Glycemic control |
| url | https://doi.org/10.1038/s41598-025-85628-5 |
| work_keys_str_mv | AT jiezhang safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes AT xincao safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes AT kaima safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes AT yizhoujiang safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes AT xiangrongqin safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes AT xiaoyongwang safetyandeffectivenessofdualtherapyforhelicobacterpyloriinfectionandtheeffectontheglycatedhemoglobinlevelintype2diabetes |